NCT00171158View on ClinicalTrials.gov

An Extension Study of the Safety and Anti-leukemic Effects of Imatinib Mesylate in Participants With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in Blast Crisis

PHASE2CompletedINTERVENTIONAL
Enrollment

260

Participants

Timeline

Start Date

July 26, 1999

Primary Completion Date

April 30, 2013

Study Completion Date

April 22, 2013

Conditions
Philadelphia Chromosome Positive CML
Interventions
DRUG

imatinib mesylate

Trial Locations (10)

60637

University of Chicago, Chicago

77030

MD Anderson Cancer Center, Houston

02115

Dana Faber Institute, Boston

Unknown

Novartis Investigative Site, Poitiers

Novartis Investigative Site, Frankfurt am Main

Novartis Investigative Site, Leipzig

Novartis Investigative Site, Mannheim

Novartis Investigative Site, München

Novartis Investigative Site, Bologna

Novartis Investigative Site, Monza

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY